DK1747204T3 - Tri-substituerede urinstoffer som cytokin-inhibitorer - Google Patents

Tri-substituerede urinstoffer som cytokin-inhibitorer

Info

Publication number
DK1747204T3
DK1747204T3 DK05740166T DK05740166T DK1747204T3 DK 1747204 T3 DK1747204 T3 DK 1747204T3 DK 05740166 T DK05740166 T DK 05740166T DK 05740166 T DK05740166 T DK 05740166T DK 1747204 T3 DK1747204 T3 DK 1747204T3
Authority
DK
Denmark
Prior art keywords
tri
substituted ureas
cytokine inhibitors
cytokine
inhibitors
Prior art date
Application number
DK05740166T
Other languages
English (en)
Inventor
Todd Andrew Brugel
Jennifer Anne Townes
Michael Philip Clark
Mark Sabat
Adam Golebiowski
Biswanath De
Stephen Matthew Berberich
Gregory Kent Bosch
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of DK1747204T3 publication Critical patent/DK1747204T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK05740166T 2004-04-22 2005-04-20 Tri-substituerede urinstoffer som cytokin-inhibitorer DK1747204T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56474504P 2004-04-22 2004-04-22
PCT/US2005/013869 WO2005105758A1 (en) 2004-04-22 2005-04-20 Tri-substituted ureas as cytokine inhibitors

Publications (1)

Publication Number Publication Date
DK1747204T3 true DK1747204T3 (da) 2008-11-10

Family

ID=34967029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05740166T DK1747204T3 (da) 2004-04-22 2005-04-20 Tri-substituerede urinstoffer som cytokin-inhibitorer

Country Status (27)

Country Link
US (2) US7402589B2 (da)
EP (2) EP1747204B1 (da)
JP (2) JP2007534689A (da)
KR (1) KR100883937B1 (da)
CN (2) CN1946700A (da)
AR (2) AR050411A1 (da)
AT (1) ATE402927T1 (da)
AU (1) AU2005238484A1 (da)
BR (1) BRPI0510128A (da)
CA (2) CA2564589A1 (da)
DE (1) DE602005008581D1 (da)
DK (1) DK1747204T3 (da)
ES (1) ES2311223T3 (da)
HR (1) HRP20080489T3 (da)
IL (1) IL178459A0 (da)
MA (1) MA28638B1 (da)
MX (2) MXPA06012189A (da)
NO (1) NO20065142L (da)
PE (2) PE20060258A1 (da)
PL (1) PL1747204T3 (da)
PT (1) PT1747204E (da)
RU (1) RU2338739C2 (da)
SI (1) SI1747204T1 (da)
SM (1) SMAP200600037A (da)
TW (2) TW200538105A (da)
WO (2) WO2005105758A1 (da)
ZA (1) ZA200609326B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
MXPA01009077A (es) * 1999-03-12 2002-03-27 Boehringer Ingelheim Pharma Composiciones heterociclicos aromaticos como agentes anti-inflamatorios.
JP2004531571A (ja) * 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
EP1408950B1 (en) * 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases

Also Published As

Publication number Publication date
EP1737830A1 (en) 2007-01-03
RU2338739C2 (ru) 2008-11-20
ES2311223T3 (es) 2009-02-01
BRPI0510128A (pt) 2007-10-02
AU2005238484A1 (en) 2005-11-10
WO2005105758A1 (en) 2005-11-10
US7402589B2 (en) 2008-07-22
HRP20080489T3 (en) 2008-11-30
PT1747204E (pt) 2008-10-29
AR048874A1 (es) 2006-06-07
TW200538105A (en) 2005-12-01
PE20060258A1 (es) 2006-04-24
MXPA06012188A (es) 2007-01-17
EP1747204B1 (en) 2008-07-30
RU2006140694A (ru) 2008-06-20
NO20065142L (no) 2006-11-08
CN1946700A (zh) 2007-04-11
CN1946701A (zh) 2007-04-11
ZA200609326B (en) 2007-12-27
KR100883937B1 (ko) 2009-02-18
US20050245555A1 (en) 2005-11-03
CA2564589A1 (en) 2005-11-10
PL1747204T3 (pl) 2009-01-30
IL178459A0 (en) 2007-02-11
SMP200600037B (it) 2006-11-22
TW200539883A (en) 2005-12-16
WO2005105757A1 (en) 2005-11-10
SMAP200600037A (it) 2006-11-22
MXPA06012189A (es) 2007-01-17
JP2007534689A (ja) 2007-11-29
US20050239811A1 (en) 2005-10-27
JP2007534688A (ja) 2007-11-29
US7449474B2 (en) 2008-11-11
CA2564587A1 (en) 2005-11-10
ATE402927T1 (de) 2008-08-15
MA28638B1 (fr) 2007-06-01
AR050411A1 (es) 2006-10-25
DE602005008581D1 (en) 2008-09-11
SI1747204T1 (sl) 2008-12-31
EP1747204A1 (en) 2007-01-31
PE20060338A1 (es) 2006-05-09
KR20060133110A (ko) 2006-12-22

Similar Documents

Publication Publication Date Title
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
LTPA2016036I1 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1711481T4 (da) Krystallinsk monohydrat som kinaseinhibitorer
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2308841T3 (da) Phlorizinanaloge som SGLT2-inhibitorer
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
NO20076678L (no) Glutamataggrekanaseinhibitorer
DK1819670T3 (da) 12-Aryl-prostaglandinanaloger
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
DK1937671T3 (da) Benzimidazolthiophenforbindelser som PLK-inhibitorer
DK1711177T3 (da) 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
DK1713805T3 (da) Kinaseinhibitorer
DK1865940T3 (da) Alfaketoamidforbindelser som cysteinproteasehæmmere
ATE418545T1 (de) Nnrt-inhibitoren